SOURCE: CannaPharmaRx, Inc.

CannaPharmaRx, Inc. Logo

April 15, 2015 10:18 ET

Viridian Capital Launches the First Institutional Report on CannaPharmaRx

NEW YORK, NY--(Marketwired - April 15, 2015) - Viridian Capital & Research, the first Wall Street investment bank and advisory platform dedicated to the Cannabis market, is pleased to announce that it has launched coverage of CannaPharmaRx, Inc. (OTCQB: CPMD), an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery. The initiation of coverage report is a 51-page document that provides an in-depth analysis of CannaPharmaRx's technology, market opportunity, business model, growth strategy, management team and overall positioning in the Biotechnology and Specialty Pharmaceutical market.

The report is available by logging onto Viridian's website at www.ViridianCR.com

CannaPharmaRx is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. The Company is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology.

Mr. Gerry Crocker, CannaPharmaRx's CEO, commented, "We have put together a world-class management team that has launched over 100 molecules for major pharmaceutical companies, managed distribution channels for $9 billion in annual sales, served as a network administrator for 240 specialty pharmacies, and raised more than $750 million in capital for startup pharmaceutical companies. Since the formation of CannaPharmaRx last year, we have made rapid progress in our mission to lay the foundation to provide safe and effective cannabinoid-based medicines to the public."

Mr. Scott Greiper, President of Viridian Capital & Research, stated, "The impressive track record of the CannaPharmaRx team and its mission to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development provides a significant opportunity for growth. We believe that a traditional "Wall Street" report is the best way to position the Company to the global investment community and create awareness of CannaPharmaRx's growth potential."

About CannaPharmaRx
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed system of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit www.CannaPharmaRx.com.

About Viridian Capital & Research, LLC
Viridian Capital & Research, LLC is a specialized boutique banking and strategic advisory firm that provides research, investment banking, investor relations and corporate development services to emerging growth companies in the cannabis sector. Our banking practice, through broker-dealer Pickwick Capital Partners, provides capital and M&A to fund the growth of our clients, while our advisory practice helps to position and build their business. Leveraging our team's decades of high level operating and transactional experience on Wall Street, in industry and in the government, we provide flexible comprehensive strategic and financial solutions that assist cannabis enterprises in realizing their full potential. For more information, please visit http://www.viridiancr.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • Contact:

    Investor Relations for Viridian Capital & Research:
    Michael Swartz
    Analyst
    Viridian Capital & Research, LLC
    212-333-0257
    mswartz@viridiancr.com

    Investor Relations for CannaPharmaRx:
    Bridamary Rosario
    856-376-0500
    bbrosario@cannapharmarx.com